Premium Company Profile: Depomed

Summary

Depomed is a specialty pharmaceutical company engaged in the development and commercialization of products that are based on its oral drug delivery technologies. Depomed's business strategy is using its proprietary drug delivery technology AcuForm to potential product candidates of its own and other pharmaceutical companies.

Scope

• Contains corporate strategy, value chain presence and SWOT Analysis
• Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
• Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Depomed's marketed products Glumetza and Proquin are related to indications Type II Diabetes and urinary tract infections respectively.

Depomed derives its revenues from sales of its products, royalties and license and collaboration fees. Depomed's current operating plan focuses on maximizing the revenues through license and collaboration arrangements with other pharma and biotech companies and commercializing of its existing product portfolio.

The company's total revenues increased at a CAGR of 54.8% during 2002-2006, from $1.7 million to $9.6 million. The company's biggest contributor to revenue growth during 2002-2006 was revenues from license and collaboration growing at a CAGR of 22.3% during 2002-2006.

Reasons to Purchase

• Access all the important information and analysis on the company in a single report
• Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
• Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content